NZ590283A - Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors - Google Patents
Imidazolylpyrimidine compounds as hdac and / or cdk inhibitorsInfo
- Publication number
- NZ590283A NZ590283A NZ590283A NZ59028309A NZ590283A NZ 590283 A NZ590283 A NZ 590283A NZ 590283 A NZ590283 A NZ 590283A NZ 59028309 A NZ59028309 A NZ 59028309A NZ 590283 A NZ590283 A NZ 590283A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- fibrosis
- methylimidazol
- benzamide
- pyrimidin
- Prior art date
Links
- FKTSKGMJQQGFHN-UHFFFAOYSA-N 2-(1h-imidazol-2-yl)pyrimidine Chemical class C1=CNC(C=2N=CC=CN=2)=N1 FKTSKGMJQQGFHN-UHFFFAOYSA-N 0.000 title abstract 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 title 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 abstract 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 2
- 102000003964 Histone deacetylase Human genes 0.000 abstract 2
- 108090000353 Histone deacetylase Proteins 0.000 abstract 2
- 208000008839 Kidney Neoplasms Diseases 0.000 abstract 2
- 206010038389 Renal cancer Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004761 fibrosis Effects 0.000 abstract 2
- 201000010982 kidney cancer Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 206010014733 Endometrial cancer Diseases 0.000 abstract 1
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 abstract 1
- 208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010036805 Progressive massive fibrosis Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000015634 Rectal Neoplasms Diseases 0.000 abstract 1
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 abstract 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 208000024770 Thyroid neoplasm Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 201000010048 endomyocardial fibrosis Diseases 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 206010028537 myelofibrosis Diseases 0.000 abstract 1
- YMLQRYKINUKINE-UHFFFAOYSA-N n-(2-aminophenyl)-4-[[4-(2-methyl-3-propan-2-ylimidazol-4-yl)pyrimidin-2-yl]-(2,2,2-trifluoroethyl)amino]benzamide Chemical compound CC(C)N1C(C)=NC=C1C1=CC=NC(N(CC(F)(F)F)C=2C=CC(=CC=2)C(=O)NC=2C(=CC=CC=2)N)=N1 YMLQRYKINUKINE-UHFFFAOYSA-N 0.000 abstract 1
- FGBPHRIWQHJOSZ-UHFFFAOYSA-N n-(2-aminophenyl)-4-[ethyl-[4-(2-methyl-3-propan-2-ylimidazol-4-yl)pyrimidin-2-yl]amino]benzamide Chemical compound N=1C=CC(C=2N(C(C)=NC=2)C(C)C)=NC=1N(CC)C(C=C1)=CC=C1C(=O)NC1=CC=CC=C1N FGBPHRIWQHJOSZ-UHFFFAOYSA-N 0.000 abstract 1
- QLRQHJBGBSBLSA-UHFFFAOYSA-N n-(2-aminophenyl)-4-[methyl-[4-(2-methyl-3-propan-2-ylimidazol-4-yl)pyrimidin-2-yl]amino]benzamide Chemical compound CC(C)N1C(C)=NC=C1C1=CC=NC(N(C)C=2C=CC(=CC=2)C(=O)NC=2C(=CC=CC=2)N)=N1 QLRQHJBGBSBLSA-UHFFFAOYSA-N 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 206010038038 rectal cancer Diseases 0.000 abstract 1
- 201000001275 rectum cancer Diseases 0.000 abstract 1
- 201000002793 renal fibrosis Diseases 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 201000002510 thyroid cancer Diseases 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8042608P | 2008-07-14 | 2008-07-14 | |
| PCT/US2009/050558 WO2010009139A2 (en) | 2008-07-14 | 2009-07-14 | Imidazolyl pyrimidine inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ590283A true NZ590283A (en) | 2012-11-30 |
Family
ID=41061109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ590283A NZ590283A (en) | 2008-07-14 | 2009-07-14 | Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8134000B2 (enExample) |
| JP (2) | JP5640005B2 (enExample) |
| AU (1) | AU2009271003A1 (enExample) |
| CA (1) | CA2729909A1 (enExample) |
| NZ (1) | NZ590283A (enExample) |
| WO (1) | WO2010009139A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009002534A1 (en) * | 2007-06-26 | 2008-12-31 | Gilead Colorado, Inc. | Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
| EP2303841A1 (en) * | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| EP2303881A2 (en) * | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| JP5640005B2 (ja) | 2008-07-14 | 2014-12-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｄａｃおよび／またはｃｄｋ阻害剤としてのイミダゾシルピリジン化合物 |
| KR20110038159A (ko) * | 2008-07-28 | 2011-04-13 | 길리애드 사이언시즈, 인코포레이티드 | 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물 |
| JP2012501344A (ja) | 2008-08-29 | 2012-01-19 | トレヴェンティス コーポレイション | アミロイド症を治療する組成物及び方法 |
| AU2009289649B2 (en) | 2008-09-03 | 2016-05-05 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
| WO2010075542A1 (en) | 2008-12-23 | 2010-07-01 | Curis, Inc. | Cdk inhibitors |
| ES2463826T3 (es) * | 2009-06-08 | 2014-05-29 | Gilead Sciences, Inc. | Compuestos inhibidores de HDAC de cicloalquilcarbamato benzamida anilina |
| CA2763786C (en) | 2009-06-08 | 2014-09-30 | Gilead Sciences, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
| US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| WO2012118782A1 (en) | 2011-02-28 | 2012-09-07 | Repligen Corporation | Histone deacetylase inhibitors |
| US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| WO2012149540A1 (en) | 2011-04-28 | 2012-11-01 | The Broad Institute Inc | Inhibitors of histone deacetylase |
| WO2013006408A1 (en) * | 2011-07-01 | 2013-01-10 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
| EP2877444B1 (en) | 2012-07-27 | 2020-09-02 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| US9914717B2 (en) | 2012-12-20 | 2018-03-13 | The Broad Institute, Inc. | Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
| RU2665554C2 (ru) | 2013-03-15 | 2018-08-31 | Байомарин Фармасьютикал Инк. | Ингибиторы hdac |
| WO2018098250A1 (en) * | 2016-11-22 | 2018-05-31 | Development Center For Biotechnology | Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof |
| CA3058695A1 (en) | 2017-04-26 | 2018-11-01 | Basilea Pharmaceutica International AG | Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof |
| CN108929312A (zh) * | 2017-05-22 | 2018-12-04 | 南开大学 | 具有cdk或hdac抑制活性的新型苯并杂环联嘧啶抑制剂 |
| CA3125731A1 (en) | 2018-01-12 | 2019-07-18 | KDAc Therapeutics, Inc. | Combination of a selective histone deacetylase 3 (hdac3) inhibitor and an immunotherapy agent for the treatment of cancer |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| CN109761842B (zh) * | 2019-02-01 | 2021-11-30 | 浙江工业大学 | α-F-β-NHAc-羰基化合物的合成方法 |
| WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
| WO2020223469A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer |
| WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
| WO2021030537A1 (en) | 2019-08-14 | 2021-02-18 | Incyte Corporation | Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors |
| CR20220170A (es) | 2019-10-11 | 2022-10-10 | Incyte Corp | Aminas bicíclicas como inhibidoras de la cdk2 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| CN114105958B (zh) * | 2021-12-03 | 2022-11-22 | 郑州大学第一附属医院 | 一组含羟肟酸的2-苯氨基嘧啶类衍生物及其应用 |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| WO2023118507A2 (en) | 2021-12-22 | 2023-06-29 | Augustine Therapeutics | Compounds and use thereof as hdac6 inhibitors |
| WO2024261328A1 (en) * | 2023-06-21 | 2024-12-26 | Augustine Therapeutics | Amide-amine compounds and use thereof as hdac6 inhibitors |
| WO2024261327A1 (en) * | 2023-06-21 | 2024-12-26 | Augustine Therapeutics | 2-(heteroaryl-thio)-1-(heteroaryl)ethanone compounds and use thereof as hdac6 inhibitors |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4129993B2 (ja) | 1996-01-16 | 2008-08-06 | ブリストル―マイヤーズ・スクイブ・カンパニー | ミクロソーム・トリグリセリド転移プロテインの立体配座制限芳香族抑制剤および方法 |
| US20020168761A1 (en) | 2000-01-24 | 2002-11-14 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
| US20040006011A1 (en) | 1996-07-12 | 2004-01-08 | Gour Barbara J. | Peptidomimetic modulators of cell adhesion |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| US6307049B1 (en) | 1998-09-30 | 2001-10-23 | The Procter & Gamble Co. | Heterocyclic 2-substituted ketoamides |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| CZ2002961A3 (cs) | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
| US20020065303A1 (en) | 2000-02-01 | 2002-05-30 | Bing-Yan Zhu | Bivalent phenylene inhibitors of factor Xa |
| EP1277754B8 (en) | 2000-04-27 | 2005-09-28 | Astellas Pharma Inc. | Imidazopyridine derivatives |
| US6403588B1 (en) | 2000-04-27 | 2002-06-11 | Yamanouchi Pharmaceutical Co., Ltd. | Imidazopyridine derivatives |
| AU2001273040A1 (en) | 2000-06-27 | 2002-01-08 | Du Pont Pharmaceuticals Company | Factor xa inhibitors |
| GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| WO2002026712A2 (en) | 2000-09-29 | 2002-04-04 | Millennium Pharmaceuticals, Inc. | Quaternary amines and related inhibitors of factor xa |
| WO2002034748A1 (fr) | 2000-10-24 | 2002-05-02 | Sankyo Company, Limited | Derives d'imidazopyridine |
| US7429599B2 (en) | 2000-12-06 | 2008-09-30 | Signal Pharmaceuticals, Llc | Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK |
| US7129242B2 (en) | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| SE0100569D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | New compounds |
| BR0207096A (pt) | 2001-02-20 | 2004-01-20 | Astrazeneca Ab | Uso de um composto, compostos, formulação farmacêutica, e, método de tratamento e/ou profilaxia de condições associadas com a inibição de glicogênio sintase quinase-3 |
| CA2442654A1 (en) | 2001-04-10 | 2002-10-10 | Transtech Pharma, Inc. | Probes, systems, and methods for drug discovery |
| KR20040018281A (ko) | 2001-06-21 | 2004-03-02 | 스미스클라인 비참 코포레이션 | 포진 바이러스 감염의 예방 및 치료를 위한 이미다조[1，２－α]피리딘 유도체 |
| CA2450555A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| EP1270551A1 (en) | 2001-06-26 | 2003-01-02 | Aventis Pharma Deutschland GmbH | Urea derivatives with antiproteolytic activity |
| US7868204B2 (en) * | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US7244740B2 (en) | 2001-10-05 | 2007-07-17 | Smithkline Beecham Corporation | Imidazo-pyridine derivatives for use in the treatment of herpes viral infection |
| DE60225316T2 (de) | 2001-11-13 | 2009-02-26 | AXYS Pharmaceuticals, Inc., South San Francisco | Cyanoalkylamino-derivate als protease-hemmer |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| JP2003313126A (ja) | 2002-04-23 | 2003-11-06 | Sankyo Co Ltd | イミダゾピリジン誘導体を有効成分とする医薬 |
| JP2004002826A (ja) | 2002-04-24 | 2004-01-08 | Sankyo Co Ltd | 高分子イミダゾピリジン誘導体 |
| GB0212049D0 (en) | 2002-05-24 | 2002-07-03 | Merck Sharp & Dohme | Therapeutic agents |
| US20040034084A1 (en) | 2002-05-24 | 2004-02-19 | Celgene Corporation | Methods for using JNK inhibitors for treating or preventing disease-related wasting |
| CA2388358A1 (en) | 2002-05-31 | 2003-11-30 | Voiceage Corporation | A method and device for multi-rate lattice vector quantization |
| UA80296C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Imidazolopyridines and methods of making and using the same |
| EP1551795A1 (en) | 2002-10-17 | 2005-07-13 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US20040087642A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
| US20040092568A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods for the treatment, prevention and management of macular degeneration |
| WO2004048343A1 (en) | 2002-11-28 | 2004-06-10 | Schering Aktiengesellschaft | Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| US20050019366A1 (en) | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
| TW200424174A (en) | 2003-02-06 | 2004-11-16 | Hoffmann La Roche | New TP diamide |
| US7208491B2 (en) | 2003-02-07 | 2007-04-24 | Hoffmann-La Roche Inc. | N-monoacylated o-phenylenediamines |
| WO2004076452A1 (en) | 2003-02-26 | 2004-09-10 | Merck Sharp & Dohme Limited | 5,8-DIFLUOROIMIDAZO[1,2-a]PYRIDINES AS GABA-A α2/α3 LIGANDS FOR TREATING ANXIETY AND/OR DEPRESSION |
| US7320989B2 (en) | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
| EP1603900A4 (en) | 2003-03-06 | 2008-08-20 | Merck & Co Inc | IMIDAZOPYRIDIN COMPOUNDS WITH EFFECT AGAINST PROTOZOEN |
| PT1611088E (pt) | 2003-04-07 | 2009-09-24 | Pharmacyclics Inc | Hidroxamatos como agentes terapêuticos |
| CA2521915A1 (en) | 2003-04-15 | 2004-10-28 | Pfizer Inc. | Alpha substituted carboxylic acid as ppar modulators |
| US20050234066A1 (en) | 2004-04-15 | 2005-10-20 | Agouron Pharmaceuticals, Inc. | Alpha substituted carboxylic acids |
| US20050187266A1 (en) | 2003-04-15 | 2005-08-25 | Pfizer Inc | Alpha substituted carboxylic acids |
| CN102584813B (zh) | 2003-05-14 | 2016-07-06 | Ngc药物公司 | 化合物及其在调节淀粉样蛋白β中的用途 |
| GB0311276D0 (en) * | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| WO2005006945A2 (en) | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| AU2004276337B2 (en) | 2003-09-24 | 2009-11-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
| EP2210607B1 (en) | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
| EP1684690A4 (en) | 2003-11-06 | 2008-10-15 | Celgene Corp | METHODS OF USE AND COMPOSITIONS COMPRISING A JNK INHIBITOR FOR THE TREATMENT AND MANAGEMENT OF ASBESTOS-RELATED DISEASES AND DISORDERS |
| US7524851B2 (en) | 2003-12-05 | 2009-04-28 | Robert Bosch Gesellschaft Fur Medizinische Forschung (Rbmf) | Diagnostic methods for therapeutic compounds and methods for monitoring azathioprine therapy |
| US7429590B2 (en) | 2003-12-10 | 2008-09-30 | Merck & Co. Inc. | Antiprotozoal imidazopyridine compounds |
| US7671181B2 (en) | 2004-01-16 | 2010-03-02 | Merck Sharp & Dohme Corp. | Polynucleotides encoding coccidian parasite casein kinase I, a chemotherapeutic target for antiprotozoal agents |
| WO2005077368A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| WO2005077373A2 (en) | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Treatment of gastro-esophageal reflux disease (gerd) |
| DE102004008141A1 (de) | 2004-02-19 | 2005-09-01 | Abbott Gmbh & Co. Kg | Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren |
| US20070093492A1 (en) | 2004-03-09 | 2007-04-26 | Weir-Torn Jiaang | Pyrrolidine derivatives |
| AU2005225471B2 (en) | 2004-03-26 | 2011-05-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US7253204B2 (en) | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
| JP2007533730A (ja) | 2004-04-20 | 2007-11-22 | アブ サイエンス | 筋炎および筋ジストロフィーを含む炎症性筋疾患を処置するためのｃ−ｋｉｔ阻害剤の使用法 |
| WO2005102318A1 (en) | 2004-04-20 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating hiv related diseases |
| NZ550114A (en) | 2004-04-20 | 2011-02-25 | Transtech Pharma Inc | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
| US20080004279A1 (en) | 2004-04-23 | 2008-01-03 | Alain Moussy | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases |
| EP1742633A2 (en) | 2004-04-23 | 2007-01-17 | AB Science | Use of c-kit inhibitors for treating fibrosis |
| WO2005102326A2 (en) | 2004-04-23 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating renal diseases |
| US20070249628A1 (en) | 2004-05-18 | 2007-10-25 | Alain Moussy | Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons |
| WO2005115385A1 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
| WO2005115304A2 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating fibrodysplasia |
| HRP20120327T1 (hr) | 2004-07-28 | 2012-05-31 | Janssen Pharmaceutica Nv | Supstituirani indolil alkil amino derivati kao novi inhibitori histonske deacetilaze |
| WO2006038001A1 (en) | 2004-10-06 | 2006-04-13 | Celltech R & D Limited | Aminopyrimidine derivatives as jnk inhibitors |
| AU2005295734A1 (en) | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
| JP2008520730A (ja) | 2004-11-23 | 2008-06-19 | セルジーン・コーポレーション | 中枢神経系傷害の治療用ｊｎｋ阻害剤 |
| BRPI0516915A (pt) | 2004-12-01 | 2008-03-11 | Devgen Nv | derivados de tiazol substituìdos por 5-carboxamido que interagem com canais de ìons, particularmante com canais de ìons da famìlia kv |
| US20090099160A1 (en) | 2004-12-17 | 2009-04-16 | David Andrews | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors |
| JPWO2006070943A1 (ja) | 2004-12-28 | 2008-06-12 | 武田薬品工業株式会社 | 縮合イミダゾール化合物およびその用途 |
| US20090048285A1 (en) | 2005-01-19 | 2009-02-19 | Benjamin Pelcman | Pyrrolopyridines Useful in the Treatment of Inflammation |
| GB0504753D0 (en) * | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
| WO2006108059A1 (en) | 2005-04-06 | 2006-10-12 | Exelixis, Inc. | C-met modulators and methods of use |
| AU2006244203B2 (en) | 2005-05-09 | 2012-05-03 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
| JP4528918B2 (ja) | 2005-06-21 | 2010-08-25 | 学校法人 関西大学 | カルボキサミド誘導体 |
| JP2008546802A (ja) | 2005-06-24 | 2008-12-25 | ジェネラブズ テクノロジーズ インコーポレーティッド | ウイルスを治療するためのヘテロアリール誘導体 |
| US7309787B2 (en) | 2005-07-13 | 2007-12-18 | Allergan, Inc. | Kinase inhibitors |
| EP1904065A2 (en) | 2005-07-14 | 2008-04-02 | AB Science | Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma |
| CN101304736A (zh) | 2005-09-07 | 2008-11-12 | 雪兰诺实验室公司 | 治疗子宫内膜异位症的ikk抑制剂 |
| RU2405770C2 (ru) | 2005-09-27 | 2010-12-10 | Сионоги Энд Ко., Лтд. | Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2 |
| AU2006296386A1 (en) | 2005-09-30 | 2007-04-05 | Astrazeneca Ab | Imidazo [1,2-a] pyridine having anti-cell-proliferation activity |
| UY29827A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones |
| ITMI20060296A1 (it) | 2006-02-17 | 2007-08-18 | Alberto Lodolo | Dispositivo di intercettazione multifunzionale |
| CA2644933A1 (en) | 2006-02-27 | 2007-09-07 | Gilead Colorado, Inc. | Combinations comprising a histone deacetylase inhibiting agent and a nuclear hormone receptor ligand for treating cardiovascular conditions |
| WO2007127137A2 (en) | 2006-04-26 | 2007-11-08 | Merck & Co., Inc. | Disubstituted aniline compounds |
| SG174772A1 (en) * | 2006-09-11 | 2011-10-28 | Curis Inc | Multi-functional small molecules as anti-proliferative agents |
| WO2009002534A1 (en) | 2007-06-26 | 2008-12-31 | Gilead Colorado, Inc. | Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
| EP2303841A1 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| JP5640005B2 (ja) | 2008-07-14 | 2014-12-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｄａｃおよび／またはｃｄｋ阻害剤としてのイミダゾシルピリジン化合物 |
| EP2303881A2 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases |
| KR20110038159A (ko) | 2008-07-28 | 2011-04-13 | 길리애드 사이언시즈, 인코포레이티드 | 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물 |
| CA2763786C (en) | 2009-06-08 | 2014-09-30 | Gilead Sciences, Inc. | Alkanoylamino benzamide aniline hdac inihibitor compounds |
| ES2463826T3 (es) | 2009-06-08 | 2014-05-29 | Gilead Sciences, Inc. | Compuestos inhibidores de HDAC de cicloalquilcarbamato benzamida anilina |
-
2009
- 2009-07-14 JP JP2011518843A patent/JP5640005B2/ja not_active Expired - Fee Related
- 2009-07-14 CA CA2729909A patent/CA2729909A1/en not_active Abandoned
- 2009-07-14 AU AU2009271003A patent/AU2009271003A1/en not_active Abandoned
- 2009-07-14 US US12/502,870 patent/US8134000B2/en not_active Expired - Fee Related
- 2009-07-14 NZ NZ590283A patent/NZ590283A/xx not_active IP Right Cessation
- 2009-07-14 WO PCT/US2009/050558 patent/WO2010009139A2/en not_active Ceased
-
2014
- 2014-01-07 JP JP2014000744A patent/JP2014058583A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010009139A3 (en) | 2010-07-08 |
| WO2010009139A2 (en) | 2010-01-21 |
| US8134000B2 (en) | 2012-03-13 |
| JP2014058583A (ja) | 2014-04-03 |
| CA2729909A1 (en) | 2010-01-21 |
| AU2009271003A1 (en) | 2010-01-21 |
| JP5640005B2 (ja) | 2014-12-10 |
| JP2011528039A (ja) | 2011-11-10 |
| US20100009990A1 (en) | 2010-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ590320A (en) | Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases | |
| Guo et al. | Discovery of pyrroloaminopyrazoles as novel PAK inhibitors | |
| Huynh et al. | Optimization of pyrazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1) | |
| Buchholz et al. | The first potent inhibitors for human glutaminyl cyclase: Synthesis and structure− activity relationship | |
| Huang et al. | Discovery of 3-[2-(imidazo [1, 2-b] pyridazin-3-yl) ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl) phenyl} benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant | |
| Li et al. | Discovery of a series of 2, 5-diaminopyrimidine covalent irreversible inhibitors of Bruton’s tyrosine kinase with in vivo antitumor activity | |
| US9284298B2 (en) | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | |
| WO2007149395A3 (en) | 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer | |
| Luckhurst et al. | Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor | |
| Davey et al. | Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors | |
| BR0311343A (pt) | Derivados de piridazina | |
| Muth et al. | Tri-and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c‑Jun N‑Terminal Kinase 3 | |
| MX2009003090A (es) | Genes novedosos relacionados con ciclasa de glutaminilo. | |
| MX2010002938A (es) | Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer. | |
| TW200619218A (en) | Pyrimidines as PLK inhibitors | |
| TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
| US20130252942A1 (en) | Quinazoline carboxamide azetidines | |
| NZ600927A (en) | N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as pde10a inhibitors | |
| WO2005113515A8 (de) | Pyrimidine als plk inhibitoren | |
| Richter et al. | Difluoro-dioxolo-benzoimidazol-benzamides as potent inhibitors of CK1δ and ε with nanomolar inhibitory activity on cancer cell proliferation | |
| ES3009926T3 (en) | Compounds and compositions for modulating egfr mutant kinase activities | |
| MX2011012353A (es) | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus. | |
| UA97817C2 (ru) | Гетероциклические производные 4-(метилсульфонил)фенила и их применение | |
| ATE469154T1 (de) | Pyrazolopyrimidine als zellzyklus-kinasehemmer | |
| WO2008017361A3 (de) | 2-(heterocyclylbenzyl)-pyridazinonderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 JUL 2016 BY COMPUTER PACKAGES INC Effective date: 20130726 |
|
| LAPS | Patent lapsed |